impact of coalterations on kras-mutant nsclc
Published 4 years ago • 86 plays • Length 3:41Download video MP4
Download video MP3
Similar videos
-
4:43
understanding nsclc treatment when you have a kras mutation
-
2:12
advances in the management of kras-mutant nsclc
-
4:42
kras-mutant nsclc: current systemic treatment options
-
1:37
treatment strategies for kras-mutant nsclc with co-mutations
-
5:57
kras mutation subtypes in advanced nsclc
-
4:03
landscape of targeted therapies in lung cancer
-
5:15
lung cancer treatment
-
6:14
understanding biomarker testing in non-small cell lung cancer
-
1:10
targeting non-g12c kras mutations in nsclc
-
2:31
how do doctors treat lung cancer with kras mutations?
-
1:08
what is a kras mutation in non-small cell lung cancer (nsclc)?
-
1:25
challenges of kras-targeting for lung cancer therapy
-
3:20
history of kras-targeting in clinical trials
-
3:44
using liquid biopsy to predict the detrimental effects of icis in kras-mutant nsclc
-
3:10
counseling patients with nsclc when kras is detected
-
4:41
history of kras testing in advanced nsclc
-
3:53
the impact of kras mutation and pd-1 status on outcomes of sbrt for nsclc
-
3:57
future directions in managing kras-mutant advanced nsclc
-
0:35
data on kras inhibitors in lung cancer at wclc 2022
-
1:10
current treatment strategies krasg12c–mutated nsclc
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
1:54
dr. langer discusses the impact of targeted therapy in nsclc